SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:umu-12934"
 

Sökning: onr:"swepub:oai:DiVA.org:umu-12934" > Autoantibody format...

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha

Eriksson, Catharina, 1955- (författare)
Umeå universitet,Klinisk immunologi
Engstrand, S (författare)
Umeå universitet,Reumatologi
Sundqvist, K-G (författare)
Karolinska Institutet,Umeå universitet,Klinisk immunologi
visa fler...
Rantapää-Dahlqvist, Solbritt (författare)
Umeå universitet,Reumatologi
visa färre...
 (creator_code:org_t)
2004-07-22
2005
Engelska.
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 64:3, s. 403-407
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Research on autoantibody formation in patients treated with TNFα inhibitors has produced contradictory results. Objective: To study the prevalence of autoantibodies in patients with rheumatoid arthritis treated with the TNFα inhibitor infliximab. Methods: 53 patients (48 female, 11 male) treated with infliximab for rheumatoid arthritis were followed for autoantibody production before treatment and after 14, 30, and 54 weeks. Six patients treated with etanercept were studied for comparison. The analyses included antibodies against nuclear antigens (ANA), extractable nuclear antigens, double stranded (ds)DNA (by ELISA, IIF on Crithidia luciliae for IgM and IgG, and Farr assay), nucleosomes, cardiolipin, smooth muscle, mitochondria, proteinase 3, and myeloperoxidase antigens. Results: The number of patients treated with infliximab who developed antibodies against dsDNA of both IgG and IgM class (tested by IIF) increased significantly. The prevalence of patients positive for IgG class increased to 66% at 30 weeks and 45% at 54 weeks, and of IgM class to 85% and 70%, respectively. The titre and number of patients expressing antibodies against nucleosomes and ANA also increased significantly. The number of rheumatoid factor or anticardiolipin positive patients was stable and there was no increase in antibodies against the other antigens. A lupus-like syndrome was seen in one patient. No patient treated with etanercept developed any of these autoantibodies. Conclusions: Patients treated with infliximab may develop anti-dsDNA antibodies of both IgM and IgG class, anti-nucleosome antibodies, and ANA, with a gradual increase until 30 weeks.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Immunology in the medical area (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Nyckelord

Adult
Aged
Antibodies; Antinuclear/biosynthesis
Antibodies; Monoclonal/adverse effects/*immunology/therapeutic use
Antirheumatic Agents/adverse effects/*immunology/therapeutic use
Arthritis; Rheumatoid/drug therapy/*immunology
Autoantibodies/*biosynthesis
DNA/immunology
Drug Hypersensitivity/etiology
Drug Therapy; Combination
Female
Humans
Immunoglobulin G/biosynthesis
Immunoglobulin M/biosynthesis
Male
Middle Aged
Clinical immunology
Klinisk immunologi
Rheumatology
Reumatologi
Clinical Immunology
klinisk immunologi
reumatologi
rheumatology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy